Skip to content
cccskills
FreePublished on GitHub

endo-cgm-vs-smbg-t1d-mdi

Recommends using continuous glucose monitoring instead of fingerstick self-monitoring for type 1 diabetes patients on multiple daily injections to reduce hypoglycemia risk. Use when a clinician evaluates glucose monitoring options for T1D on MDIs or manages hypoglycemia-prone T1D patients.

The English summary is being prepared. Showing the original description.

Run score Not tested

See how to install

Files included (1)

  • SKILL.md2.3 KB

SKILL.md (original)

Review the instructions the agent will receive before you install.

Continuous Glucose Monitoring vs Self-Monitoring of Blood Glucose for Type 1 Diabetes on Multiple Daily Injections

STEP 1 — Gather Information

Confirm diagnosis of type 1 diabetes, current insulin regimen (multiple daily injections), history of hypoglycemia or hypoglycemia unawareness, patient’s ability to use CGM device, access to supplies, and interest in real-time glucose data.

STEP 2 — Rule In / Rule Out

Rule in: Patient has T1D and is using MDIs. Rule out: Patient is not on MDIs (e.g., using insulin pump) or does not have T1D; if ruled out, consider alternative monitoring strategies per other guidelines.

STEP 3 — Classify or Stratify

Stratify by hypoglycemia risk: higher priority for CGM in patients with hypoglycemia unawareness, frequent nocturnal hypoglycemia, fear of hypoglycemia, or impaired awareness of hypoglycemia (IAH); lower priority but still recommended for all T1D on MDIs.

STEP 4 — Decide

Recommend initiating real-time CGM rather than SMBG by fingerstick; provide comprehensive CGM education and ensure continued access to SMBG for sensor validation, warm‑up periods, and symptom‑glucose mismatches.

Clinical Guardrails / Mimics / Pitfalls

Do not rely solely on CGM without SMBG backup; do not skip patient education on device use and troubleshooting; avoid CGM use if patient cannot afford supplies or has uncontrolled skin irritation from adhesives; remember that SMBG remains necessary for calibration/validation and during sensor warm‑up.

Concrete Clinical Example

A 22‑year‑old college student with T1D on MDI reports twice‑weekly nocturnal hypoglycemia and fear of sleeping; after CGM initiation with structured education, hypoglycemia episodes drop from 8 per month to 2, and SMBG is used twice daily to verify sensor accuracy.

Source: Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596

Reviews

No reviews yet. Tell others what you thought.

Comments

No login needed. Share how it worked for you, ask a question, or note where it did not run.

No comments yet. Be the first to write one.

Comments are published right away. Do not include personal information such as email addresses or phone numbers. Up to 2 URLs.

0 / 1,000 characters

This form is protected by reCAPTCHA, and the Google Privacy Policy and Terms of Service apply.

More skills from this repository

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

See all skills by dromlakhani

Report a problem with this skill